For health care professionals in EUROPE except those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
2X RISK OF DEATH5
5X RISK OF STROKE5
3X RISK OF DEVELOPING HEART FAILURE5
The AF mortality risk rises dramatically over time if the condition is not appropriately treated.6
The AF mortality risk rises dramatically over time if the condition is not appropriately treated.6
The AF mortality risk rises dramatically over time if the condition is not appropriately treated.6
You see first-hand the debilitating impact of Atrial Fibrillation (AF) on your patients’ wellbeing and quality of life and know the risks it carries. Rate control medications may help manage symptoms in some patients, but they do not prevent AF episodes or prevent disease progression.
In many cases, the antiarrhythmic drugs (AADs) used for rhythm control fail to control AF or their effectiveness declines over time,7 while the bleeding risk linked to oral anticoagulation (OAC) therapy is also an important consideration.
The longer paroxysmal AF is not adequately managed with medication, the greater the risk patients have it progressing to persistent or permanent forms.5,8
There is an alternative - a proven minimally invasive catheter procedure that treats the symptoms of AF and is now recommended by NICE as a treatment option for AF.9
Catheter ablation is recommended by the 2024 European Society of Cardiology (ESC) as a first-line treatment strategy for paroxysmal AF; catheter ablation is also advised for certain other AF patients.5
A new generation of catheter ablation technology for the treatment of Atrial Fibrillation that’s transforming safety outcomes and patients’ lives.
The AF mortality risk rises dramatically over time if the condition is not appropriately treated.6
#1 DOCTOR-RECOMMENDED PULSED FIELD ABLATION (PFA) PROCEDURE WORLDWIDE9
BACKED BY 10 YEARS OF RESEARCH…9-15,16
… AND >150 PUBLICATIONS16
500,000
Patients treated with FARAPULSE
Catheter ablation is recommended by the 2024 European Society of Cardiology (ESC) as a first-line treatment strategy for paroxysmal AF; catheter ablation is also advised for certain other AF patients.5
FIRST-LINE RHYTHM CONTROL THERAPY
Classa
Levelb
Catheter ablation is recommended as a first-line option with a shared decision-making rhythm control strategy in patients with paroxysmal AF (Atrial Fibrillation), to reduce symtoms, recurrence, and progression of AF.
1
A
AF PATIENTS RESISTANT OR INTOLERANT TO ANTIARRHYTHMIC DRUG THERAPY
Classa
Levelb
Catheter ablation is recommended in patients with paroxysmal or persistent AF resistant or intolerant to antiarrhythmic drug therapy to reduce symptoms, recurrence, and progression of AF.
1
A
PATIENTS WITH HEART FAILURE
Classa
Levelb
AF catheter ablation is recommended in patients with AF and HFrEF (Heart Failure with reduced Ejection Fraction) with high probability of tachycardia-induced cardiomyopathy to reverse left ventricular dysfunction.
1
B
Table adapted from Recommendation Table 18, 2024 ESC Guidelines for the Management of Atrial Fibrillation.5
a Class of recommendation
b Level of evidence
REFERENCES:
1. Linz D, Gawalko M, Betz K, et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur. 2024;1;37:100786. doi: 10.1016/j.lanepe.2023.100786.
2. Zuin M, Malagù M, Vitali F, et al. Trends in atrial fibrillation-related mortality in Europe, 2008–2019. Eur Heart J Qual Care Clin Outcomes. 2024;10(5):467-478. doi.org/10.1093/ehjqcco/qcae007
3. ESC press release available at: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Atrial-fibrillation-set-to-affect-more-than-14-million-over-65s-in-the-EU-by-2060. Last accessed May 2025.
4. Krijthe BP, Kunst A, Benjamin EJ. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J.2013; 34(35):2746-51. doi: 10.1093/eurheartj/eht280.
5. Van Gelder IC, Rienstra M, Bunting KV et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal (2024) 00, 1–101 https://doi.org/10.1093/eurheartj/ehae176.
6. Joglar JA, Chung MK, Armbruster AL et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1–e156. doi: 10.1161/CIR.0000000000001193
7. Kheiri B, Simpson TF, Przybylowicz R, et al. Ablation Versus Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation: A Meta-Analysis of Randomized Trials. Circ Arrhythm Electrophysiol. 20217;14(8):e009692. doi: 10.1161/CIRCEP.120.009692.
8. Poole JE, Bahnson TD, Monahan KH et al. CABANA Investigators and ECG Rhythm Core Lab. Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. J Am Coll Cardiol. 2020 Jun 30;75(25):3105–3118. doi: 0.1016/j.jacc.2020.04.065.
9. NICE guidance IPG806: Pulsed-field ablation for atrial fibrillation. Last accessed July 2025.
10. BSC data on file. 2025
11. Reddy VY, et al., Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II JACC: Clinical Electrophysiology 7.5 (2021): 614-627. doi:0.1016/j.jacep.2021.02.014
12. Schmidt B, Bordignon S, Tohoku S, et al. 5S Study: Safe and Simple Single Shot Pulmonary Vein Isolation With Pulsed Field Ablation Using Sedation. Circ Arrhythm Electrophysiol. 2022 Jun;15(6):e010817. doi: 10.1161/CIRCEP.121.010817.
13. Turagam MK, Neuzil P, Schmidt B, et al. Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation. 2023;148:35–46. DOI: 10.1161/CIRCULATIONAHA.123.064959
14. Ekanem, E., Neuzil, P., Reichlin, T. et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med (2024). doi.org/10.1038/s41591-024-03114-3
15. Reddy VY, Gerstenfeld EP, et al; ADVENT Investigators. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023 Nov 2;389(18):1660-1671. doi: 10.1056/NEJMoa2307291.
16. Füting A, Neven K, Howel D et al. Patient discomfort following pulsed field ablation for paroxysmal atrial fibrillation – an assessment of chest and groin pain using the Numeric Rating Scale. Clin Res Cardiol (2021). 10.1007/s00392-021-01933-9
17. FARAPULSE Clinical Compendium.
CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
